Enekinragene inzadenovec - Pacira BioSciences
Alternative Names: FX 201 - Flexion Therapeutics; GQ 203; Humantakinogene hadenovec; PCRX-201Latest Information Update: 07 Mar 2025
At a glance
- Originator Baylor College of Medicine
- Developer Flexion Therapeutics
- Class Anti-inflammatories; Antirheumatics; Gene therapies
- Mechanism of Action Gene transference; Interleukin-1 receptor antagonist expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 07 Mar 2025 Phase-I development in Osteoarthritis is ongoing in USA (Intra-articular, Injection) (NCT04119687)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Osteoarthritis in USA (Intra-articular, Injection)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Pain in USA (Intra-articular, Injection)